Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Trial of Rituximab vs Alemtuzumab vs Alemtuzumab + Rituximab as Consolidation Therapy for Patients With Chronic Lymphocytic Leukemia (CLL) With Evidence of Residual Disease Following Prior Chemo(Immuno)Therapy.

Next Previous
Search
Trial Profile

A Randomized Trial of Rituximab vs Alemtuzumab vs Alemtuzumab + Rituximab as Consolidation Therapy for Patients With Chronic Lymphocytic Leukemia (CLL) With Evidence of Residual Disease Following Prior Chemo(Immuno)Therapy.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Jan 2010 Status changed from recruiting to active, no longer recruiting according to M.D. Anderson Cancer Center record
    • 15 Oct 2008 Integrated ClinicalTrials.gov record NCT00771602.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top